[go: up one dir, main page]

NO20013971L - Fremgangsmåte ved fremstilling av (2R)-2-propyloktansyre - Google Patents

Fremgangsmåte ved fremstilling av (2R)-2-propyloktansyre

Info

Publication number
NO20013971L
NO20013971L NO20013971A NO20013971A NO20013971L NO 20013971 L NO20013971 L NO 20013971L NO 20013971 A NO20013971 A NO 20013971A NO 20013971 A NO20013971 A NO 20013971A NO 20013971 L NO20013971 L NO 20013971L
Authority
NO
Norway
Prior art keywords
preparation
propyloctanoic acid
acid
propyloctanoic
octanoic acid
Prior art date
Application number
NO20013971A
Other languages
English (en)
Other versions
NO20013971D0 (no
Inventor
Norikazu Toda
Kaoru Yamaguchi
Youichi Iguchi
Original Assignee
Tokyo Kasei Kogyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tokyo Kasei Kogyo Co Ltd filed Critical Tokyo Kasei Kogyo Co Ltd
Publication of NO20013971D0 publication Critical patent/NO20013971D0/no
Publication of NO20013971L publication Critical patent/NO20013971L/no

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
    • B01J23/38—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals
    • B01J23/40—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals of the platinum group metals
    • B01J23/42—Platinum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J21/00—Catalysts comprising the elements, oxides, or hydroxides of magnesium, boron, aluminium, carbon, silicon, titanium, zirconium, or hafnium
    • B01J21/18—Carbon
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/347—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups
    • C07C51/36—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups by hydrogenation of carbon-to-carbon unsaturated bonds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Health & Medical Sciences (AREA)
  • Materials Engineering (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Catalysts (AREA)

Abstract

Fremgangsmåte ved fremstillingen av (2R)-2-propyloktansyre som erå underkaste (2S)-2-(2-propynyl)-oktansyre eller (2S)-2-(2-propenyl)oktansyre reduksjon ved å anvende platina på karbon.Denne fremgangsmåte gir (2R)-2-propyloktansyre med høy op-I tisk renhet uten isomerisasjon.
NO20013971A 1999-02-18 2001-08-15 Fremgangsmåte ved fremstilling av (2R)-2-propyloktansyre NO20013971L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP3975899 1999-02-18
PCT/JP2000/000900 WO2000048982A1 (en) 1999-02-18 2000-02-17 Process for the preparation of (2r)-2-propyloctanoic acid

Publications (2)

Publication Number Publication Date
NO20013971D0 NO20013971D0 (no) 2001-08-15
NO20013971L true NO20013971L (no) 2001-08-15

Family

ID=12561862

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20013971A NO20013971L (no) 1999-02-18 2001-08-15 Fremgangsmåte ved fremstilling av (2R)-2-propyloktansyre

Country Status (19)

Country Link
US (1) US6608221B1 (no)
EP (3) EP1153910B1 (no)
JP (2) JP4752989B2 (no)
KR (1) KR100666423B1 (no)
CN (4) CN1907938A (no)
AT (1) ATE359256T1 (no)
AU (1) AU776927B2 (no)
BR (1) BR0008261A (no)
CA (1) CA2364308C (no)
DE (1) DE60034316T2 (no)
ES (1) ES2283287T3 (no)
HU (1) HUP0200358A3 (no)
MX (1) MXPA01008241A (no)
NO (1) NO20013971L (no)
NZ (1) NZ513569A (no)
RU (1) RU2297406C2 (no)
TW (1) TWI268921B (no)
WO (1) WO2000048982A1 (no)
ZA (1) ZA200106500B (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI268921B (en) * 1999-02-18 2006-12-21 Ono Pharmaceutical Co A process for preparing (2R)-2-propyloctanoic acid
WO2003007992A1 (en) 2001-07-18 2003-01-30 Ono Pharmaceutical Co., Ltd. Remedies for brain ischemic diseases
JP2005298334A (ja) * 2001-12-19 2005-10-27 Ono Pharmaceut Co Ltd 新規な中間体化合物およびそれを用いる化合物の製造方法
WO2005032538A1 (ja) * 2003-10-03 2005-04-14 Ono Pharmaceutical Co., Ltd. (２ｒ)−２−プロピルオクタン酸を有効成分とする輸液製剤
CN1889942B (zh) * 2003-10-03 2010-12-15 小野药品工业株式会社 包含(2r)-2-丙基辛酸作为活性成分的药物
US7928143B2 (en) * 2003-10-03 2011-04-19 Ono Pharmaceutical Co., Ltd. Method for preventing and/or treating neurodegenerative diseases
JP4730303B2 (ja) * 2004-04-28 2011-07-20 小野薬品工業株式会社 （２ｒ）−２−プロピルオクタン酸とアミンとからなる結晶
CN101056842A (zh) * 2004-11-16 2007-10-17 默克公司 治疗中风的(2r)－2－丙基辛酸前药
WO2006075596A1 (ja) * 2005-01-13 2006-07-20 Kuraray Co., Ltd. ２－アリルカルボン酸化合物の製造方法
EP2266559A1 (en) 2005-03-15 2010-12-29 Ono Pharmaceutical Co., Ltd. Therapeutic agent for ophthalmic disease
JP5050851B2 (ja) 2005-06-27 2012-10-17 小野薬品工業株式会社 疼痛治療剤
AU2006305309A1 (en) 2005-10-18 2007-04-26 Ono Pharmaceutical Co., Ltd. Pharmaceutical for protection of motor nerve in patient with amyotrophic lateral sclerosis
US20090203783A1 (en) 2005-12-22 2009-08-13 Ono Pharmaceutical Co., Ltd. Therapeutic agent for acute cerebral infarct
US20090118542A1 (en) * 2006-02-16 2009-05-07 Shigeya Yamazaki Process for Production of Optically Active Carboxlic Acid Compound
EP2015741A4 (en) * 2006-05-04 2009-12-23 Merck & Co Inc HISTONDEACETYLASE INHIBITORS FOR THE TREATMENT OF NEURODE GENERATION
CN102417445B (zh) * 2011-11-05 2013-11-13 中国科学院山西煤炭化学研究所 一种由马来酸合成丁二酸的方法
CN102675166B (zh) * 2012-05-11 2014-03-26 山东齐都药业有限公司 用于制备2-丙基庚酸的新中间体、其制备方法及2-丙基庚酸的制备方法
CN102786407B (zh) * 2012-08-15 2014-04-16 湖北大学 一种制备(2r)-2-丙基辛酸的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2317019A1 (de) * 1972-04-27 1973-11-08 Upjohn Co Neue 4,5-didehydro-prostaglandine
JPH0672123B2 (ja) * 1986-08-21 1994-09-14 セントラル硝子株式会社 トリフルオロメチル基を有するシクロヘキサンカルボン酸の製造方法
JP2868183B2 (ja) * 1988-02-29 1999-03-10 株式式社三和化学研究所 光学活性を有する４−オキソ−１−ベンゾピラン−２−カルボン酸誘導体の製法、その合成用中間体並びに該中間体の製法
US5202474A (en) * 1989-06-22 1993-04-13 Monsanto Company Asymmetric catalytic hydrogenation of α-arylpropenoic acids
DE69408373T2 (de) * 1993-06-01 1998-07-16 Ono Pharmaceutical Co Pentansäurederivate
JP3032447B2 (ja) * 1995-04-24 2000-04-17 小野薬品工業株式会社 光学活性な２−プロピルオクタン酸の製造方法
JP3084345B2 (ja) * 1995-04-26 2000-09-04 小野薬品工業株式会社 光学活性な２−プロピルオクタン酸の製造方法
TW509672B (en) * 1998-05-12 2002-11-11 Ono Pharmaceutical Co Novel intermediate compounds and processes for the production of optical active octanoic acid derivatives
TWI268921B (en) * 1999-02-18 2006-12-21 Ono Pharmaceutical Co A process for preparing (2R)-2-propyloctanoic acid
JP4730303B2 (ja) * 2004-04-28 2011-07-20 小野薬品工業株式会社 （２ｒ）−２−プロピルオクタン酸とアミンとからなる結晶

Also Published As

Publication number Publication date
CN100430364C (zh) 2008-11-05
BR0008261A (pt) 2002-01-15
JP4752989B2 (ja) 2011-08-17
EP1153910A4 (en) 2002-08-07
NO20013971D0 (no) 2001-08-15
EP1153910A1 (en) 2001-11-14
ES2283287T3 (es) 2007-11-01
TWI268921B (en) 2006-12-21
DE60034316T2 (de) 2008-01-03
CN1907938A (zh) 2007-02-07
CA2364308A1 (en) 2000-08-24
ZA200106500B (en) 2003-02-07
WO2000048982A1 (en) 2000-08-24
EP1721882A1 (en) 2006-11-15
RU2297406C2 (ru) 2007-04-20
CN1183082C (zh) 2005-01-05
AU776927B2 (en) 2004-09-23
JP2010248198A (ja) 2010-11-04
MXPA01008241A (es) 2002-08-30
DE60034316D1 (de) 2007-05-24
CA2364308C (en) 2010-02-02
JP5343925B2 (ja) 2013-11-13
AU2573000A (en) 2000-09-04
HUP0200358A3 (en) 2003-03-28
CN1341091A (zh) 2002-03-20
ATE359256T1 (de) 2007-05-15
RU2001125501A (ru) 2004-02-20
CN101100422A (zh) 2008-01-09
NZ513569A (en) 2003-01-31
KR20010102161A (ko) 2001-11-15
US6608221B1 (en) 2003-08-19
EP1714956A1 (en) 2006-10-25
CN1636957A (zh) 2005-07-13
HUP0200358A2 (hu) 2002-05-29
EP1153910B1 (en) 2007-04-11
KR100666423B1 (ko) 2007-01-11

Similar Documents

Publication Publication Date Title
NO20013971L (no) Fremgangsmåte ved fremstilling av (2R)-2-propyloktansyre
Endo et al. Mode of inhibition of β-hydroxydecanoyl thioester dehydrase by 3-decynoyl-N-acetylcysteamine
Kimura et al. Evidence for two different forms of guanylate cyclase in rat heart
Baertschi et al. Absolute configuration of cis-12-oxophytodienoic acid of flaxseed: implications for the mechanism of biosynthesis from the 13 (S)-hydroperoxide of linolenic acid
EP0308573A3 (en) Intermediates useful in the preparation of dopamine-beta-hydroxylase inhibitors
Boeynaems et al. Transformation of arachidonic acid into an iodolactone by the rat thyroid.
ES2020981B3 (es) Fenilsulfonamidas sustituidas.
IL128205A0 (en) Potassium channel inhibitors and pharmaceutical compositions containing the same
BR0016665A (pt) Composição alvejante, e, métodos de alvejamento e de preparação de uma composição alvejante
ATE96764T1 (de) Herstellung von basischen aluminiumhalogeniden.
BR9917007A (pt) Moduladores de ccr5
NO962490L (no) Orale formuleringer av S(+)-ibuprofen
Majeski et al. Controlled potential oxidation of anthracene in acetonitrile. II
AU5317279A (en) Hydroxypropyl-triazole derivatives and their use as antimycotic agents
ZA832044B (en) Imidazolyphenyl-tetrahydropyridazines,processes for their preparation and pharmaceutical preparation containing them
ES549776A0 (es) Procedimiento para la preparacion de pirrolo-bencimidazoles
Sourkes et al. Reduction of methionine sulfoxides by Escherichia coli
AU4152893A (en) Preparation of basic aluminium halides
SE7905659L (sv) Medel for behandling av seborreiska tillstand
Jackson et al. Effect of heat on some collagen cross-links
BR9816072A (pt) Composição clareadora da pele contendo um composto de ácido ascórbico
AU581185B2 (en) Process for the racemization of optically active aminoacids
DK0471252T3 (da) N-Alkyl-N-(meth)acryloyloxyalkylcarboxamider af aromatiske carboxylsyrer og af aromatiske carboxylsyreanhydrider samt klæbestoffer, som indeholder disse forbindelser
Russell et al. The effects of sulfhydryl reagents on the activity of wheat germ uroporphyrinogen I synthase
IT8620561A0 (it) Procedimento e dispositivo per il trattamento di prodotti di uovo, o relativi composti, per prolungare la durata dei prodotti medesimi.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application